Tags

Type your tag names separated by a space and hit enter

Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?
Proc Nutr Soc 2015; 74(1):5-12PN

Abstract

There is increasing scientific interest in the field of vitamin D research, moving the focus beyond bone health to other disease processes. Low circulating vitamin D levels have been reported as a risk factor for several pathophysiologically divergent diseases, including cancers, diabetes, CVD, multiple sclerosis and inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). But, therein, remains the challenge: can any single nutrient contribute to multiple complex disease mechanisms and, ultimately, have therapeutic potential? The aim of this review is to critically evaluate several strands of scientific evidence surrounding vitamin D and inflammation, primarily focusing on IBD. Epidemiological studies suggest an increased incidence of IBD and rheumatoid arthritis in countries of more northern latitudes, mirroring sunlight patterns. A considerable body of evidence supports the anti-inflammatory effects of vitamin D, at least in animal models of IBD. Although it is accepted that suboptimal vitamin D status is common in IBD, some studies suggest that this associates with more severe disease. With regard to treatment, the data are only beginning to emerge from randomised controlled trials to suggest that people with IBD may remain in remission longer when treated with oral vitamin D. In conclusion, several strands of evidence suggest that vitamin D may modify the immune response in IBD. There is a continued need for large well-designed clinical trials and mechanistic studies to determine if, and how, this emerging promise translates into tangible clinical benefits for people with chronic debilitating diseases such as IBD.

Authors+Show Affiliations

Department Clinical Medicine,Trinity College Dublin,Centre for Health Sciences,St James' Hospital,Dublin 8,Ireland.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25490986

Citation

O'Sullivan, Maria. "Vitamin D as a Novel Therapy in Inflammatory Bowel Disease: New Hope or False Dawn?" The Proceedings of the Nutrition Society, vol. 74, no. 1, 2015, pp. 5-12.
O'Sullivan M. Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn? Proc Nutr Soc. 2015;74(1):5-12.
O'Sullivan, M. (2015). Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn? The Proceedings of the Nutrition Society, 74(1), pp. 5-12. doi:10.1017/S0029665114001621.
O'Sullivan M. Vitamin D as a Novel Therapy in Inflammatory Bowel Disease: New Hope or False Dawn. Proc Nutr Soc. 2015;74(1):5-12. PubMed PMID: 25490986.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn? A1 - O'Sullivan,Maria, Y1 - 2014/12/10/ PY - 2014/12/11/entrez PY - 2014/12/11/pubmed PY - 2015/8/28/medline KW - 25(OH)D 25-hydroxyvitamin D KW - Autoimmune disease KW - CD Crohn's disease KW - CDAI Crohn's disease activity index KW - CRP C-reactive protein KW - IBD inflammatory bowel disease KW - Inflammatory bowel disease KW - Nutrition KW - RCT randomised controlled trial KW - UC ulcerative colitis KW - Vitamin D SP - 5 EP - 12 JF - The Proceedings of the Nutrition Society JO - Proc Nutr Soc VL - 74 IS - 1 N2 - There is increasing scientific interest in the field of vitamin D research, moving the focus beyond bone health to other disease processes. Low circulating vitamin D levels have been reported as a risk factor for several pathophysiologically divergent diseases, including cancers, diabetes, CVD, multiple sclerosis and inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). But, therein, remains the challenge: can any single nutrient contribute to multiple complex disease mechanisms and, ultimately, have therapeutic potential? The aim of this review is to critically evaluate several strands of scientific evidence surrounding vitamin D and inflammation, primarily focusing on IBD. Epidemiological studies suggest an increased incidence of IBD and rheumatoid arthritis in countries of more northern latitudes, mirroring sunlight patterns. A considerable body of evidence supports the anti-inflammatory effects of vitamin D, at least in animal models of IBD. Although it is accepted that suboptimal vitamin D status is common in IBD, some studies suggest that this associates with more severe disease. With regard to treatment, the data are only beginning to emerge from randomised controlled trials to suggest that people with IBD may remain in remission longer when treated with oral vitamin D. In conclusion, several strands of evidence suggest that vitamin D may modify the immune response in IBD. There is a continued need for large well-designed clinical trials and mechanistic studies to determine if, and how, this emerging promise translates into tangible clinical benefits for people with chronic debilitating diseases such as IBD. SN - 1475-2719 UR - https://www.unboundmedicine.com/medline/citation/25490986/Vitamin_D_as_a_novel_therapy_in_inflammatory_bowel_disease:_new_hope_or_false_dawn L2 - https://www.cambridge.org/core/product/identifier/S0029665114001621/type/journal_article DB - PRIME DP - Unbound Medicine ER -